Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Outcome Health Announces Partnership with American Liver Foundation to Promote Updated Screening Recommendations for Hepatitis C

Outcome Health announced a partnership with the American Liver Foundation to raise awareness of liver disease, specifically hepatitis C.

Read More »

JHL Biotech Receives Positive CHMP Scientific Advice for Global Phase III Clinical Trial of Proposed Bevacizumab Biosimilar to Treat Lung Cancer

JHL Biotech received a positive Scientific Advice from the Committee for Medicinal Products for Human Use of the European Medicines Agency related to the EU approval pathway for its proposed bevacizumab biosimilar JHL1149 to treat patients with non-small cell lung cancer.

Read More »

FDA Approves Malaria Drug Arakoda

The U.S. FDA approved 60 Degrees Pharmaceuticals’ Arakoda (tafenoquine) tablets for the prevention of malaria in patients aged 18 years and older.

Read More »

Regeneron Reports Second Quarter 2018 Financial and Operating Results

Regeneron Pharmaceuticals Inc. reported important commercial progress in the second quarter with continued strong U.S. sales growth for Eylea in retinal diseases and Dupixent in atopic dermatitis.

Read More »

FDA approves first treatment for rare adrenal tumors

The FDA approved Azedra injection for intravenous use for treating patients age 12 and older with rare tumors of the adrenal gland that cannot be surgically removed, have spread beyond the original tumor site and require systemic anticancer therapy.

Read More »

BioLineRx, Merck Expand Immuno-Oncology Collaboration in Pancreatic Cancer

BioLineRx Ltd. announced the expansion of its immuno-oncology collaboration with Merck & Co. Inc. for the support of a Phase 2a program investigating BioLineRx’s BL-8040 in combination with Merck’s anti-PD-1 therapy Keytruda (pembrolizumab) in patients with metastatic pancreatic cancer.

Read More »

Anima Biotech, Lilly Reach Potential $1+ Billion Deal

Anima Biotech announced a deal with Eli Lilly for the discovery and development of translation inhibitors for several target proteins by using Anima’s Translation Control Therapeutics platform.

Read More »

PTC Therapeutics to Acquire Agilis Biotherapeutics

PTC Therapeutics Inc. announced an agreement to acquire Agilis Biotherapeutics Inc., a biotechnology company advancing an innovative gene therapy platform for rare monogenic diseases that affect the central nervous system.

Read More »

FDA Approves Janssen’s Symtuza for HIV-1 Infection

The U.S. FDA approved Symtuza, the first complete darunavir-based single-tablet regimen for the treatment of human immunodeficiency virus type 1 in treatment-naïve and certain virologically suppressed adults.

Read More »

Eisai Announces Positive Topline Results from Large-Scale Cardiovascular Outcome Trial for Anti-Obesity Agent Belviq

Eisai Inc. announced positive top-line results from the CAMELLIA-TIMI 61 cardiovascular outcome trial.

Read More »

Huntsworth Adds Giant Creative Strategy to Evoke Group

Huntsworth plc acquired San Francisco-based Giant Creative Strategy from Shamrock Capital, a Los Angeles-based investment firm, adding to its collection of leading health and wellness marketing companies under the Evoke Group.

Read More »

FDA approves the first drug with an indication for treatment of smallpox

The U.S. FDA approved TPOXX (tecovirimat), the first drug with an indication for the treatment of smallpox.

Read More »

U.S. FDA Approves Xtandi for Treatment of Men with Non-Metastatic Castration-Resistant Prostate Cancer

Astellas Pharma Inc. and Pfizer Inc. announced the U.S. FDA approved a supplemental New Drug Application for Xtandi (enzalutamide), following FDA Priority Review designation.

Read More »

Amgen, UCB Resubmit Biologics License Application For Evenity To U.S. FDA

Amgen and UCB announced the resubmission of the Biologics License Application to the U.S. FDA for Evenity (romosozumab), an investigational monoclonal antibody for the treatment of osteoporosis in postmenopausal women at high risk for fracture.

Read More »

Havas Group Appoints James Wright Global Chairman Havas PR Collective And CEO Havas PR North America

The Havas Group announced the appointment of James Wright as Global Chairman, Havas PR Collective, and CEO of Havas PR North America.

Read More »

Bausch + Lomb Announces FDA Filing Acceptance

Bausch + Lomb announced the U.S. FDA accepted the New Drug Application for the company’s sub-micron loteprednol etabonate ophthalmic gel 0.38% with a PDUFA date of Feb. 25, 2019.

Read More »

Health Canada Approves Erleada for nmCRPC

The Janssen Pharmaceutical Companies of Johnson & Johnson announced that Health Canada approved Erleada (apalutamide tablets), an oral treatment for patients with non-metastatic castration-resistant prostate cancer.

Read More »

Landmark Study Shows Precision Medicine Benefits Pancreatic Cancer Patients

A study published today by the Pancreatic Cancer Action Network, Perthera Inc., and colleagues in the AACR journal Clinical Cancer Research found for the first time that precision medicine can improve outcomes and provide clinically meaningful information to pancreatic cancer patients.

Read More »

Amgen Announces Top-Line Results From Phase 3 Study Of ABP 710, Biosimilar Candidate To Infliximab

Amgen announced results from a Phase 3 study evaluating the efficacy and safety of biosimilar candidate ABP 710 compared with Remicade (infliximab) in patients with moderate-to-severe rheumatoid arthritis.

Read More »

Intouch Solutions Creates Agency Network

A full-service network, Intouch Group serves as the parent organization for six affiliates and represents Intouch Solutions’ diverse suite of capabilities and depth of service offerings.

Read More »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

June 2018 Focus: Biotech, Payer Access, DTC and more!


Ad Right Bottom

Main Navigation